Literature DB >> 1371566

Urinary prostate specific antigen levels: role in monitoring the response of prostate cancer to therapy.

R W DeVere White1, F J Meyers, S E Soares, D G Miller, T F Soriano.   

Abstract

We have shown that prostate specific antigen (PSA) levels can be as readily obtained from voided urine as from serum samples. This procedure was found to give stable and reproducible results. PSA analyses were performed on voided urine collected from 42 patients with benign prostatic hypertrophy (BPH), 27 with stage D2 prostate cancer and 57 after radical prostatectomy. The 42 BPH samples had a mean urinary PSA level of 216 ng./ml., which did not correlate with estimated prostate size. For 4 of 5 patients with stage D2 disease who presented before hormonal therapy urinary PSA levels were greater than 50 ng./ml. For 22 stage D2 patients seen after initiation of hormonal therapy the majority had low urinary PSA levels. After initiation of hormonal therapy in most cases low urinary PSA levels were found in conjunction with high serum PSA values. However, in other cases we found high urinary PSA with low serum PSA levels. Of 43 patients who underwent radical prostatectomy for stages A to C disease it was noteworthy that 77% had elevated urinary PSA levels, while only 33% had elevated serum levels. Therefore, close to 80% of these patients have prostate tissue remaining locally after this operation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1371566     DOI: 10.1016/s0022-5347(17)37430-x

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

1.  Regulation of the expression of the prostate-specific antigen by claudin-7.

Authors:  J-Y Zheng; D Yu; M Foroohar; E Ko; J Chan; N Kim; R Chiu; S Pang
Journal:  J Membr Biol       Date:  2003-08-01       Impact factor: 1.843

Review 2.  Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease.

Authors:  Richard R Drake; Krista Y White; Thomas W Fuller; Elena Igwe; Mary Ann Clements; Julius O Nyalwidhe; Robert W Given; Raymond S Lance; O John Semmes
Journal:  J Proteomics       Date:  2009-01-20       Impact factor: 4.044

3.  Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL.

Authors:  Stéphane Bolduc; Louis Lacombe; Alain Naud; Mireille Grégoire; Yves Fradet; Roland R Tremblay
Journal:  Can Urol Assoc J       Date:  2007-11       Impact factor: 1.862

4.  Early detection of prostate cancer local recurrence by urinary prostate-specific antigen.

Authors:  Stéphane Bolduc; Brant A Inman; Louis Lacombe; Yves Fradet; Roland R Tremblay
Journal:  Can Urol Assoc J       Date:  2009-06       Impact factor: 1.862

Review 5.  The present and future of prostate cancer urine biomarkers.

Authors:  Marina Rigau; Mireia Olivan; Marta Garcia; Tamara Sequeiros; Melania Montes; Eva Colás; Marta Llauradó; Jacques Planas; Inés de Torres; Juan Morote; Colin Cooper; Jaume Reventós; Jeremy Clark; Andreas Doll
Journal:  Int J Mol Sci       Date:  2013-06-17       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.